Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Tiziana Life Sciences ( (TLSA) ) is now available.
On August 14, 2025, Tiziana Life Sciences announced the enrollment and dosing of the first participant in its Phase 2a clinical trial of intranasal foralumab for Multiple System Atrophy (MSA) at Brigham and Women’s Hospital in Boston. MSA is a rare neurodegenerative disorder with no FDA-approved treatments, affecting 15,000–50,000 people in the U.S. The trial aims to assess foralumab’s potential to reduce neuroinflammation and slow disease progression through a novel delivery approach. This milestone marks a significant step in Tiziana’s mission to address neurodegenerative diseases by targeting immune processes, potentially opening new treatment avenues for conditions where inflammation and degeneration are linked.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using transformational drug delivery technologies. The company specializes in alternative routes of immunotherapy, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody. Tiziana’s innovative nasal approach aims to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods.
Average Trading Volume: 334,244
Technical Sentiment Signal: Buy
Current Market Cap: $248M
For an in-depth examination of TLSA stock, go to TipRanks’ Overview page.